接受肺癌姑息性胸部放疗患者的四级预后评分
A Four-Tiered Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer.
作者信息
Nieder Carsten, Tollåli Terje, Haukland Ellinor, Reigstad Anne, Randi Flatøy Liv, Dalhaug Astrid
机构信息
a Departments of Oncology and Palliative Medicine , Nordland Hospital Trust , Bodø , Norway.
b Department of Clinical Medicine , Faculty of Health Sciences, University of Tromsø , Tromsø , Norway.
出版信息
Cancer Invest. 2018 Jan 2;36(1):59-65. doi: 10.1080/07357907.2017.1416394. Epub 2018 Jan 10.
Palliative radiotherapy improves lung cancer related symptoms. Prognosis should be taken into account when deciding about fractionation. In this study, prognostic factors derived from multivariate analysis were used to assign a point sum reflecting 6-month survival. Four prognostic groups were compared. Performance status, lactate dehydrogenase, C-reactive protein, liver/adrenal gland metastases, and extrathoracic disease status significantly predicted survival and formed the basis of the score. The four groups had a median survival of 0.8, 1.6, 3.3, and 10.5 months (6-month survival 0, 10, 30, 70%; 12-month survival 0, 0, 12, 40%; p = 0.0001), respectively. In the unfavorable group best supportive care might be preferable.
姑息性放疗可改善肺癌相关症状。在决定分割方式时应考虑预后情况。在本研究中，采用多因素分析得出的预后因素来确定一个反映6个月生存率的积分总和。对四个预后组进行了比较。体能状态、乳酸脱氢酶、C反应蛋白、肝/肾上腺转移以及胸外疾病状态显著预测了生存率，并构成了该评分的基础。这四个组的中位生存期分别为0.8、1.6、3.3和10.5个月（6个月生存率分别为0%、10%、30%、70%；12个月生存率分别为0%、0%、12%、40%；p = 0.0001）。在预后不良组，最佳支持治疗可能更为可取。
Zotero 插件